From Summer Street: "We see the FDA approval of Triferic as a significant positive for RMTI, and we continue to believe Triferic could be a $150MM product in 2016, with EPS growing from ($0.40) in 2014 to $1.85 in 2016, a dramatic increase in earnings power for RMTI over the next two years. Net, we remain positive on Triferic following yesterday’s FDA approval, and we maintain our BUY rating and $25 price target."
...they're getting desperate. ADCOM won't be approved; then FDA won't approve; add'l ESA trial will be needed; then will be commercial failure....so sad. RMTI projects $300-600M U.S. Triferic sales and $1B global Triferic sales. Game over shorts. thanks for playing.